VANDA PHARMACEUTICALS INC (VNDA) Fundamental Analysis & Valuation

NASDAQ:VNDA • US9216591084

8.645 USD
+0.75 (+9.57%)
Last: Mar 9, 2026, 02:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VNDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VNDA. VNDA was compared to 519 industry peers in the Biotechnology industry. VNDA may be in some trouble as it scores bad on both profitability and health. VNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. VNDA Profitability Analysis

1.1 Basic Checks

  • In the past year VNDA has reported negative net income.
  • VNDA had a negative operating cash flow in the past year.
  • In multiple years VNDA reported negative net income over the last 5 years.
  • In multiple years VNDA reported negative operating cash flow during the last 5 years.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • VNDA has a Return On Assets (-45.09%) which is in line with its industry peers.
  • VNDA has a Return On Equity of -67.38%. This is comparable to the rest of the industry: VNDA outperforms 56.45% of its industry peers.
Industry RankSector Rank
ROA -45.09%
ROE -67.38%
ROIC N/A
ROA(3y)-15.86%
ROA(5y)-8.2%
ROE(3y)-23.48%
ROE(5y)-12.53%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 93.96%, VNDA belongs to the top of the industry, outperforming 94.61% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VNDA has remained more or less at the same level.
  • VNDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.28%
GM growth 5Y0.74%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VNDA Health Analysis

2.1 Basic Checks

  • VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VNDA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for VNDA has been increased compared to 5 years ago.
  • The debt/assets ratio for VNDA is higher compared to a year ago.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • VNDA has an Altman-Z score of 0.52. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
  • VNDA has a better Altman-Z score (0.52) than 61.08% of its industry peers.
  • VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • VNDA has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: VNDA outperforms 45.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.52
ROIC/WACCN/A
WACC8.73%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • VNDA has a Current Ratio of 2.39. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.39, VNDA is doing worse than 72.25% of the companies in the same industry.
  • VNDA has a Quick Ratio of 2.38. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
  • VNDA has a worse Quick ratio (2.38) than 69.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.38
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. VNDA Growth Analysis

3.1 Past

  • VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -462.50%.
  • The Revenue has grown by 8.72% in the past year. This is quite good.
  • Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.73% on average per year.
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)8.72%
Revenue growth 3Y-5.29%
Revenue growth 5Y-2.73%
Sales Q2Q%7.58%

3.2 Future

  • VNDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.51% yearly.
  • Based on estimates for the next years, VNDA will show a decrease in Revenue. The Revenue will decrease by -2.33% on average per year.
EPS Next Y-39.4%
EPS Next 2Y25.42%
EPS Next 3Y26.51%
EPS Next 5YN/A
Revenue Next Year17.93%
Revenue Next 2Y27.88%
Revenue Next 3Y27.17%
Revenue Next 5Y-2.33%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. VNDA Valuation Analysis

4.1 Price/Earnings Ratio

  • VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VNDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VNDA's earnings are expected to grow with 26.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.42%
EPS Next 3Y26.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VNDA Dividend Analysis

5.1 Amount

  • VNDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VNDA Fundamentals: All Metrics, Ratios and Statistics

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (3/9/2026, 2:40:06 PM)

8.645

+0.75 (+9.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-05
Inst Owners69.95%
Inst Owner Change-3.25%
Ins Owners8.71%
Ins Owner Change12.09%
Market Cap511.01M
Revenue(TTM)216.10M
Net Income(TTM)-220.47M
Analysts80
Price Target14.41 (66.69%)
Short Float %6.5%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.89%
Min EPS beat(2)17.82%
Max EPS beat(2)65.96%
EPS beat(4)3
Avg EPS beat(4)18.8%
Min EPS beat(4)-26.44%
Max EPS beat(4)65.96%
EPS beat(8)6
Avg EPS beat(8)-3.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.73%
Min Revenue beat(2)-6.09%
Max Revenue beat(2)-5.37%
Revenue beat(4)1
Avg Revenue beat(4)-2.08%
Min Revenue beat(4)-6.09%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-1.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.67%
PT rev (3m)20.21%
EPS NQ rev (1m)-73.02%
EPS NQ rev (3m)-70.31%
EPS NY rev (1m)-69.95%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)-12.18%
Revenue NQ rev (3m)-11.7%
Revenue NY rev (1m)-5.11%
Revenue NY rev (3m)-2.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.36
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS3.66
BVpS5.54
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.09%
ROE -67.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.96%
FCFM N/A
ROA(3y)-15.86%
ROA(5y)-8.2%
ROE(3y)-23.48%
ROE(5y)-12.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.28%
GM growth 5Y0.74%
F-Score2
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.77%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.38
Altman-Z 0.52
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)9.51%
Cap/Depr(5y)15.03%
Cap/Sales(3y)0.3%
Cap/Sales(5y)0.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-39.4%
EPS Next 2Y25.42%
EPS Next 3Y26.51%
EPS Next 5YN/A
Revenue 1Y (TTM)8.72%
Revenue growth 3Y-5.29%
Revenue growth 5Y-2.73%
Sales Q2Q%7.58%
Revenue Next Year17.93%
Revenue Next 2Y27.88%
Revenue Next 3Y27.17%
Revenue Next 5Y-2.33%
EBIT growth 1Y-271.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-579.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-594.56%
OCF growth 3YN/A
OCF growth 5YN/A

VANDA PHARMACEUTICALS INC / VNDA FAQ

What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VNDA.


What is the valuation status of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a valuation rating of 1 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.


What is the profitability of VNDA stock?

VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 2 / 10.


Can you provide the financial health for VNDA stock?

The financial health rating of VANDA PHARMACEUTICALS INC (VNDA) is 3 / 10.


What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?

The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -39.4% in the next year.